PRELIMINARY CLINICAL-TRIAL OF GADODIAMIDE INJECTION - A NEW NONIONIC GADOLINIUM CONTRAST AGENT FOR MR IMAGING

被引：15

作者：

KAPLAN, GD ^{[1
]}

AISEN, AM ^{[1
]}

ARAVAPALLI, SR ^{[1
]}

机构：

[1] UNIV MICHIGAN,DEPT RADIOL,1500 E MED CTR,ANN ARBOR,MI 48109

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1991年 / 1卷 / 01期

关键词：

BRAIN NEOPLASMS; MR STUDIES; DIAGNOSIS; SECONDARY; CONTRAST ENHANCEMENT; GADOLINIUM; HEAD; HEAD AND NECK; NEOPLASMS; SPINE; PRIMARY NEOPLASMS; SECONDARY NEOPLASMS;

D O I：

10.1002/jmri.1880010107

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The safety and efficacy of a newly developed intravenous formulation of the nonionic contrast agent gadolinium diethylenetriaminepentaacetic acid-bis(methylamide), formulated as gadodiamide injection, was investigated. In 30 patients who underwent spin-echo magnetic resonance (MR) imaging before and after contrast agent enhancement, the enhanced images had characteristics judged similar to those of images enhanced by means of available gadolinium compounds. In 15 patients, contrast agent administration was of major diagnostic help, either revealing lesions not apparent without enhancement or providing important lesion characterization. In 12 patients, the lack of abnormal enhancement patterns was important in excluding the presence of disease. In three patients, the contrast agent did not provide information additional to that obtained with the unenhanced T1- and T2-weighted images. No clinically significant changes were observed in vital signs, neurologic status, or laboratory results. The authors conclude that, in this limited series, gadodiamide injection proved to be a safe and useful MR imaging contrast agent for evaluation of the central nervous system and surrounding structures.

引用

页码：57 / 62

页数：6

共 31 条

[1]

O'Toole M, Van Wagoner M, Broschart JL, Prasad R, Leese PT, Quay SC, Nonionic MRI contrast agents: a phase I clinical trial of the safety and tolerance of S‐041 injection (abstr), Magn Reson Imaging, 7, (1989)

[2]

Karch FE, Lasagna L, Adverse drug reactions: a critical review, JAMA, 234, pp. 1236-1241, (1975)

[3]

Laniado M, Weinmann HJ, Schorner W, Felix R, Speck U, First use of Gd DTPA/dimeglumine in man, Physiol Chem Phys Med NMR, 16, pp. 157-165, (1984)

[4]

Carr DH, Brown J, Bydder GM, Et al., Gadolinium‐DTPA as a contrast agent in MRI: initial clinical experience in 20 patients, AJR, 143, pp. 215-224, (1984)

[5]

Runge VM, Schorner W, Niendorf HP, Et al., Initial clinical evaluation of gadolinium DTPA for contrast‐enhanced magnetic resonance imaging, Magn Reson Imaging, 3, pp. 27-35, (1985)

[6]

Bydder GM, Clinical application of gadolinium‐DTPA, Magnetic resonance imaging, pp. 182-200, (1988)

[7]

Stack JP, Antoun NM, Jenkins JPR, Metcalfe R, Isher-Wood I, Gadolinium‐DTPA as a contrast agent in magnetic resonance imaging of the brain, Neuroradiology, 30, pp. 145-154, (1988)

[8]

Bauer WM, Fenzl G, Vogl TH, Fink U, Lissner J, Indications for the use of Gd‐DTPA in MRI of the central nervous system: experiences in patients with cerebral and spinal diseases, Invest Radiol, 23, pp. 5286-5288, (1988)

[9]

Felix R, Schorner W, Laniado M, Et al., Brain tumors: MR imaging with gadolinium‐DTPA, Radiology, 156, pp. 681-688, (1985)

[10]

Claussen C, Laniado M, Schorner W, Et al., Gadolinium‐DTPA in MR imaging of glioblastomas and intracranial metastases, AJNR, 6, pp. 669-674, (1985)

← 1 2 3 4 →